# Safety and Efficacy of APG-157 in Head and Neck Cancer

Source: https://onco.cc/trials/nct05312710/  
OnCo record `nct05312710` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of APG-157 in head and neck squamous cell carcinoma, run by Aveta Biomics, Inc., active and no longer recruiting.

## Summary

Safety and Efficacy of APG-157 in Head and Neck Cancer is a phase 2 interventional study registered as NCT05312710 by Aveta Biomics, Inc., with 24 participants enrolled, started 2022-04-22 and due to reach its primary completion in 2026-12. Interventions recorded: APG-157.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05312710
- Phase: 2
- Setting: Phase 2 Study to Evaluate the Safety and Efficacy of APG-157 as Neoadjuvant/Induction Therapy for Patients With Head and Neck Squamous Cell Cancer (HNSCC) of the Oral Cavity and/or Oropharynx
- Sponsor: Aveta Biomics, Inc.
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT05312710: https://clinicaltrials.gov/study/NCT05312710

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- companies: [Aveta Biomics](https://onco.cc/companies/aveta-biomics/)

---
JSON: https://onco.cc/api/v1/entities/nct05312710.json